[go: up one dir, main page]

EA201001139A1 - УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB - Google Patents

УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB

Info

Publication number
EA201001139A1
EA201001139A1 EA201001139A EA201001139A EA201001139A1 EA 201001139 A1 EA201001139 A1 EA 201001139A1 EA 201001139 A EA201001139 A EA 201001139A EA 201001139 A EA201001139 A EA 201001139A EA 201001139 A1 EA201001139 A1 EA 201001139A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trkb
antibody anti
improved antibody
polynucleotides
application
Prior art date
Application number
EA201001139A
Other languages
English (en)
Other versions
EA028621B1 (ru
Inventor
Кеннет Р. Льюрсен
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201001139A1 publication Critical patent/EA201001139A1/ru
Publication of EA028621B1 publication Critical patent/EA028621B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В заявке описаны улучшенные антитела или антигенсвязывающие соединения, которые специфически связываются с рецепторной тирозинкиназой В (TrkB) или являются ее агонистами, а также способы их получения. В заявке описаны также полинуклеотиды и векторы, кодирующие такие соединения, и клетки-хозяина, включающие указанные полинуклеотиды или векторы.
EA201001139A 2008-01-17 2009-01-16 АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КОТОРЫЙ СПЕЦИФИЧНО СВЯЗЫВАЕТ РЕЦЕПТОРНУЮ ТИРОЗИНКИНАЗУ (TrkB), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, И КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ УКАЗАННУЮ КОМПОЗИЦИЮ EA028621B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2182008P 2008-01-17 2008-01-17
US61/021,820 2008-01-17
PCT/US2009/031345 WO2009092049A1 (en) 2008-01-17 2009-01-16 Improved anti-trkb antibodies

Publications (2)

Publication Number Publication Date
EA201001139A1 true EA201001139A1 (ru) 2011-04-29
EA028621B1 EA028621B1 (ru) 2017-12-29

Family

ID=40627621

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001139A EA028621B1 (ru) 2008-01-17 2009-01-16 АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КОТОРЫЙ СПЕЦИФИЧНО СВЯЗЫВАЕТ РЕЦЕПТОРНУЮ ТИРОЗИНКИНАЗУ (TrkB), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, И КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ УКАЗАННУЮ КОМПОЗИЦИЮ

Country Status (15)

Country Link
US (1) US8642035B2 (ru)
EP (1) EP2235062A1 (ru)
JP (1) JP5420568B2 (ru)
KR (1) KR101290503B1 (ru)
CN (1) CN102015769B (ru)
AR (1) AR070202A1 (ru)
AU (1) AU2009205937B2 (ru)
BR (1) BRPI0906877A2 (ru)
CA (1) CA2712298C (ru)
CL (1) CL2009000090A1 (ru)
EA (1) EA028621B1 (ru)
MX (1) MX2010007841A (ru)
PE (1) PE20091326A1 (ru)
TW (1) TW200936608A (ru)
WO (1) WO2009092049A1 (ru)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
PT2725028T (pt) 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2504024A2 (de) * 2009-09-27 2012-10-03 Ruhr-Universität Bochum Verfahren zur therapie und diagnose von morbus alzheimer
WO2011146336A1 (en) 2010-05-20 2011-11-24 Array Biopharma Inc. Macrocyclic compounds as trk kinase inhibitors
EP3798236B1 (en) * 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
CN102830228B (zh) * 2011-06-15 2015-01-21 格诺思博生物科技(上海)有限公司 定量分析循环肿瘤细胞的试剂及试剂盒
CN102944674B (zh) * 2012-11-05 2014-10-22 武汉远征世纪制药有限公司 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法
EP3485882A1 (en) * 2013-01-25 2019-05-22 Case Western Reserve University Compositions for the treatment of pervasive development disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
AU2014302313A1 (en) * 2013-06-26 2016-02-18 Baylor College Of Medicine Rett syndrome and treatments therefore
ES2941630T3 (es) 2014-11-16 2023-05-24 Array Biopharma Inc Forma cristalina de sulfato de hidrógeno de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
US9869296B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method and system to install components, such as tip extensions and winglets, to a wind turbine blade
US9869295B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method to install components, such as tip extensions and winglets, to a wind turbine blade, as well as the wind turbine blade and component
US9869297B2 (en) 2015-05-07 2018-01-16 General Electric Company Attachment method and system to install components, such as vortex generators, to a wind turbine blade
CN107849615A (zh) 2015-06-01 2018-03-27 洛克索肿瘤学股份有限公司 诊断和治疗癌症的方法
JP6816100B2 (ja) 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
US10100805B2 (en) 2015-10-12 2018-10-16 General Electric Compant Tip extension assembly for a wind turbine rotor blade
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
JP7039468B2 (ja) 2015-11-17 2022-03-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 神経およびその他の障害の処置のための結合アゴニスト
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
DK3439663T3 (da) 2016-04-04 2024-08-26 Loxo Oncology Inc Fremgangsmåder til behandling af pædiatriske cancere
PE20190437A1 (es) 2016-05-18 2019-03-27 Loxo Oncology Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
US12098202B2 (en) 2016-10-10 2024-09-24 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
US10443579B2 (en) 2016-11-15 2019-10-15 General Electric Company Tip extensions for wind turbine rotor blades and methods of installing same
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
US10830206B2 (en) 2017-02-03 2020-11-10 General Electric Company Methods for manufacturing wind turbine rotor blades and components thereof
US11098691B2 (en) 2017-02-03 2021-08-24 General Electric Company Methods for manufacturing wind turbine rotor blades and components thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018226785A1 (en) * 2017-06-06 2018-12-13 University Of Massachusetts Self-regulating aav vectors for safe expression of mecp2 in rett syndrome
US10793634B2 (en) * 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
US10913216B2 (en) 2017-11-21 2021-02-09 General Electric Company Methods for manufacturing wind turbine rotor blade panels having printed grid structures
US10821652B2 (en) 2017-11-21 2020-11-03 General Electric Company Vacuum forming mold assembly and method for creating a vacuum forming mold assembly
US11040503B2 (en) 2017-11-21 2021-06-22 General Electric Company Apparatus for manufacturing composite airfoils
US11668275B2 (en) 2017-11-21 2023-06-06 General Electric Company Methods for manufacturing an outer skin of a rotor blade
US11248582B2 (en) 2017-11-21 2022-02-15 General Electric Company Multiple material combinations for printed reinforcement structures of rotor blades
US10773464B2 (en) 2017-11-21 2020-09-15 General Electric Company Method for manufacturing composite airfoils
US11390013B2 (en) 2017-11-21 2022-07-19 General Electric Company Vacuum forming mold assembly and associated methods
US10920745B2 (en) 2017-11-21 2021-02-16 General Electric Company Wind turbine rotor blade components and methods of manufacturing the same
US10865769B2 (en) 2017-11-21 2020-12-15 General Electric Company Methods for manufacturing wind turbine rotor blade panels having printed grid structures
MX2020003550A (es) 2017-11-30 2020-08-03 Regeneron Pharma Anticuerpos monoclonales anti-trkb y metodos de uso.
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN108265036B (zh) * 2018-01-26 2021-04-27 山东大学齐鲁医院 一种沉默t1蛋白的重组病毒及其构建方法与应用
US10821696B2 (en) 2018-03-26 2020-11-03 General Electric Company Methods for manufacturing flatback airfoils for wind turbine rotor blades
US11035339B2 (en) 2018-03-26 2021-06-15 General Electric Company Shear web assembly interconnected with additive manufactured components
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CA3224985C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
CN118265719A (zh) 2022-03-30 2024-06-28 肽梦想株式会社 具有TrkB结合活性的肽复合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22979A1 (es) 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
KR20090088896A (ko) * 2006-11-09 2009-08-20 아이알엠 엘엘씨 효현제 ｔｒｋｂ 항체 및 그의 용도
US20100297115A1 (en) 2007-10-23 2010-11-25 Novartis Ag Use of trkb antibodies for the treatment of respiratory disorders

Also Published As

Publication number Publication date
CA2712298C (en) 2015-11-24
EP2235062A1 (en) 2010-10-06
US20110097326A1 (en) 2011-04-28
PE20091326A1 (es) 2009-09-18
EA028621B1 (ru) 2017-12-29
CN102015769B (zh) 2014-12-10
JP2011510021A (ja) 2011-03-31
MX2010007841A (es) 2010-09-28
CL2009000090A1 (es) 2009-07-24
AR070202A1 (es) 2010-03-17
WO2009092049A1 (en) 2009-07-23
JP5420568B2 (ja) 2014-02-19
KR101290503B1 (ko) 2013-07-26
TW200936608A (en) 2009-09-01
AU2009205937A1 (en) 2009-07-23
US8642035B2 (en) 2014-02-04
CN102015769A (zh) 2011-04-13
BRPI0906877A2 (pt) 2015-07-28
CA2712298A1 (en) 2009-07-23
AU2009205937B2 (en) 2013-02-07
KR20100103693A (ko) 2010-09-27

Similar Documents

Publication Publication Date Title
EA201001139A1 (ru) УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB
EA201790757A1 (ru) Связывающие антиген cd27l белки
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
EA202192103A1 (ru) Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EA201891066A1 (ru) Антитела к ror1
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
EA201100868A1 (ru) Противоопухолевые комбинации, содержащие антитела, специфически распознающие cd38, и цитарабин
EA201291181A1 (ru) Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
BR112014019579A8 (pt) Anticorpos, polinucleotídeos, vetores, métodos de produção de um anticorpo, heteromultímero, método de produção de um heteromultímero e célula hospedeira
EA201001223A1 (ru) Стабилизированные белковые композиции
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
NO20083053L (no) Humane monoklonale antistoffer mot O8E
EA201400933A1 (ru) Агенты, связывающие склеростин
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
EA201270174A1 (ru) Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
EA201000053A1 (ru) Новые антитела

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU